Contact Us
Plans and Services Health and Wellness About Wellmark Member Employer Broker Provider
Home Provider Communication and Resources
» Register for Wellmark.com
» Claims and Payment
» Communication and Resources
» Credentialing and Enrollment
» Health Management
» Medical, Dental, and Pharmacy
» Medical Policies and Authorizations
» Quality and Transparency
» Health Care Reform for Providers
 Printer-Friendly Page
New Medical Policy

Compounded Bioidentical Hormone Replacement Therapy

Effective Date

October 1, 2012

 

Description of Change

The use of compounded bioidentical hormone replacement therapy to treat the symptoms of menopause is considered investigational.

 

Background

Compounded bioidentical hormone products have been claimed to be safer and more effective than FDA-approved menopausal hormone therapy (MHT) drugs. At the current time, there is lack of credible medical and scientific evidence to support these claims. Additional well-designed and controlled clinical trials are needed to support the efficacy and safety of custom-compounded hormone products and to provide evidence of improved net health outcomes over conventional hormone therapies.

 


 

Wellmark.com Quick Links
» Billing Guides
» Medical Policies
» Forms
» Authorizations
» Find a Doctor or Hospital
» Drug Information
» News
» Publications
» Education
» Health Care Reform
» ICD-10
» Pre-Service Review Changes
Like Us facebook      Follow Us twitter      Watch Us youtube      Get Mobile App Download the Wellmark mobile app
 

 

© Wellmark, Inc. All Rights Reserved.
Wellmark Blue Cross and Blue Shield is an Independent Licensee of the Blue Cross and Blue Shield Association doing business in Iowa and South Dakota.
 
Privacy & Legal  |  Browser Information